Login / Signup

Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.

Andres E MartinezPaola FrattaroliChristine A VuLizy PaniaguaJoel MintzAndres Bravo-GonzalezPaola ZamudioAstrid BarcoAruna RampersadPaola LichtenbergerJose Armando Gonzales-Zamora
Published in: Vaccines (2023)
We reported a challenging case of worsening mpox after Tecovirimat treatment in the setting of new HIV and ART initiation concerning IRIS vs. Tecovirimat resistance. Clinicians should consider the risk of IRIS and weigh the pros and cons of initiating or delaying ART. In patients not responding to first-line treatment with tecovirimat, resistance testing should be performed, and alternative options should be considered. Future research is needed to establish guidance on the role of Cidofovir and Vaccinia immune globulin and the continuation of tecovirimat for refractory mpox.
Keyphrases